Industry News
Home /

News

/

Industry News

/The role of lipid components in lipid nanoparticles for vaccines and gene therapy
The role of lipid components in lipid nanoparticles for vaccines and gene therapy 2025-07-11
Review Adv Drug Deliv Rev. 2022 Sep:188:114416. doi: 10.1016/j.addr.2022.114416. Epub 2022 Jul 3.
The role of lipid components in lipid nanoparticles for vaccines and gene therapy

Abstract
Lipid nanoparticles (LNPs) play an important role in mRNA vaccines against COVID-19. In addition, many preclinical and clinical studies, including the siRNA-LNP product, Onpattro®, highlight that LNPs unlock the potential of nucleic acid-based therapies and vaccines. To understand what is key to the success of LNPs, we need to understand the role of the building blocks that constitute them. In this Review, we discuss what each lipid component adds to the LNP delivery platform in terms of size, structure, stability, apparent pKa, nucleic acid encapsulation efficiency, cellular uptake, and endosomal escape. To explore this, we present findings from the liposome field as well as from landmark and recent articles in the LNP literature. We also discuss challenges and strategies related to in vitro/in vivo studies of LNPs based on fluorescence readouts, immunogenicity/reactogenicity, and LNP delivery beyond the liver. How these fundamental challenges are pursued, including what lipid components are added and combined, will likely determine the scope of LNP-based gene therapies and vaccines for treating various diseases.

Keywords: Drug delivery; Helper lipid; Ionizable lipid; LNP; Lipid nanoparticles; Nucleic acid; PEGylated lipid; Physicochemical properties; Targeting; pK(a).

For more product information, please contact us at:
US Tel: 1-844-782-5734
US Tel: 1-844-QUAL-PEG
CHN Tel: 400-918-9898
Email: sales@sinopeg.com

Copyright © XIAMEN SINOPEG BIOTECH CO., LTD. All Rights Reserved.

Home

Products

News

contact